secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001193125-23-295566
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience reports 26% ORR in TSC1 arm, 11% in TSC2 arm from PRECISION1 interim analysis
--------------------------------------------------------------------------------

- TSC1 arm (n=22): 26% ORR (5 PRs, 4 confirmed), 42% clinical benefit rate, median 3 prior therapies.
- TSC2 arm (n=18): 11% ORR (2 PRs, 1 confirmed), 28% clinical benefit rate, 50% had ≥5 prior lines.
- No new safety signals; one grade 2 pneumonitis resolved; safety consistent with mTOR class.
- 80 patients now enrolled; two-thirds interim analysis expected 3Q 2024; trial completion by end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312523295566/0001193125-23-295566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312523295566/d572047d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-295566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer